Advertisement

Guidelines for the Use of Parkinsonian Drugs in Canada

  • Susan H. FoxEmail author
  • Sean Jeremy Udow
Living reference work entry

Abstract

Drug therapies available for patients with Parkinson’s disease (PD) in Canada are similar to all other regions of the world where the primary focus is on dopamine replacement therapies predominantly with levodopa/carbidopa and levodopa/benserazide immediate release and controlled release levodopa/carbidopa. No other levodopa preparations are available. Dopamine agonists (DA), as monotherapy or adjunct therapy, are less commonly used due to the side effect profile. Longer-acting ropinirole and pramipexole, as well as apomorphine subcutaneous infusion pump therapy, are not available in Canada. For subjects with fluctuating symptoms, add-on therapies with monoamine oxidase B inhibitors (MAOB-I), rasagiline or selegiline, and the catechol-o-methyltransferase inhibitor (COMT-I), entacapone, are commonly used options. Other MAOB inhibitors and COMT-I are not easily available. Dyskinesia can be reduced with amantadine. There are no recommended drugs for disease modification available. For the many non-motor symptoms in PD, including neuropsychiatric symptoms, autonomic failure, pain, and sleep disorders, drugs used in non-PD areas available in Canada are used.

References

  1. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. 2016;87:1274–80.CrossRefGoogle Scholar
  2. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.CrossRefGoogle Scholar
  3. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M. A multiple treatment comparison metaanalysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br J Pharmacol. 2018; 84: 1917–1927.CrossRefGoogle Scholar
  4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.CrossRefGoogle Scholar
  5. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev. 2003;2:CD003467.Google Scholar
  6. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004;21(11):687–709.CrossRefGoogle Scholar
  7. Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Movement Disorder Society Evidence-Based Medicine Committee, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33:1248–66.CrossRefGoogle Scholar
  8. Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.CrossRefGoogle Scholar
  9. Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, Wieler M, Suchowersky O, Rajput A, Lafontaine AL, Stoessl J, Moro E, Schoffer K, Miyasaki J, Hobson D, Mahmoudi M, Fox S, Postuma R, Kumar H, Jog M. Canadian guidelines on Parkinson’s disease. Can J Neurol Sci. 2012;39(4 Suppl 4):S1–30.PubMedGoogle Scholar
  10. Grimes D, Gordon J, Miyasaki J, Fon E, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Cresswell S, Kalia S, Schoffer K, Zurowski M, Postuma R, Udow S, Fox SH, Barbeau P, Fitzpatrick M, Hutton B. Canadian guideline for Parkinson disease 2nd edition. CMAJ. 2019; 36: E989-E1004.CrossRefGoogle Scholar
  11. Hill F, Miller N, Walsh RA, Mockler D, McDowell R, Walshe M. Botulinum toxin for drooling in Parkinson’s disease. Cochrane Database Syst Rev. 2016;(10):CD012408.Google Scholar
  12. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71:474–80.CrossRefGoogle Scholar
  13. Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig. 2016;36:97–107.CrossRefGoogle Scholar
  14. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429.PubMedGoogle Scholar
  15. Menza M, Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886–92.CrossRefGoogle Scholar
  16. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.CrossRefGoogle Scholar
  17. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel group trial. Lancet. 2005;365:947–54.CrossRefGoogle Scholar
  18. Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–96.CrossRefGoogle Scholar
  19. Renoux C, Dell’Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson’s disease. Br J Clin Pharmacol. 2016;82(2):461–72.CrossRefGoogle Scholar
  20. Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016;27:25–34.CrossRefGoogle Scholar
  21. Rojas-Fernandez CH, Chen Y. Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people. Can Pharm J (Ott). 2014;147(5):281–9.CrossRefGoogle Scholar
  22. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.CrossRefGoogle Scholar
  23. Seppi K, Chahine L, Chaudhuri RK, Coelho M, Heim B, Hametner EM, Djamshidian-Tehrani A, Katzenschlager R, Lim SY, Perez Lloret S, Sampaio C, Fox SH, Weintraub SH, International Parkinson and Movement Disorder Society Evidence-Based Medicine review: update on treatments for the non-motor symptoms of Parkinson’s disease. https://www.movementdisorders.org/MDS/Resources/Publications-Reviews/EBM-Reviews.htm. Accessed 9 July 2018.
  24. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169:900–6.CrossRefGoogle Scholar
  25. Wang H-F, Yu J-T, Tang S-W, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86:135–43.CrossRefGoogle Scholar
  26. Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 2018;6:242–52.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of NeurologyUniversity of TorontoTorontoCanada
  2. 2.Movement Disorder Clinic, Edmond J Safra Program in Parkinson DiseaseToronto Western HospitalTorontoCanada
  3. 3.Section of Neurology, Division of Internal MedicineUniversity of Manitoba Rady Faculty of Health SciencesWinnipegCanada
  4. 4.Movement Disorders ClinicDeer Lodge HospitalWinnipegCanada

Section editors and affiliations

  • Toshiharu Nagatsu
    • 1
    • 2
  • Akira Nakashima
    • 3
  1. 1.Fujita Health University School of MedicineToyoakeJapan
  2. 2.Institute of Environmental MedicineNagoya UniversityNagoyaJapan
  3. 3.Department of Physiological ChemistryFujita Health University School of MedicineToyoake, AichiJapan

Personalised recommendations